Because of high out-of-pocket costs of new-to-market neurologic drugs that are of similar benefit as older agents, only a small percentage of patients with neurologic disorders have access to these cutting-edge medications, new research shows."Our study of people with neurologic conditions found fewer than 20% were being treated with new medications," study author Brian C. Callaghan, MD, with University of Michigan Health in Ann Arbor, said in a statement.
[
add
]
[
|
|
...
]